Marshall Wace
FDMT icon

Marshall Wace’s 4D Molecular Therapeutics FDMT Stock Holding History

Marshall Wace’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$284K Buy
21,342
+4,614
+28% +$45K ﹤0.01% 2744
2026
Q1 		$156K Sell
16,728
-11,030
-40% -$96K ﹤0.01% 2829
2025
Q4 		$208K Sell
27,758
-118,149
-81% -$1.2M ﹤0.01% 2583
2025
Q3 		$1.27M Sell
145,907
-111,713
-43% -$668K ﹤0.01% 1835
2025
Q2 		$956K Buy
257,620
+99,332
+63% +$349K ﹤0.01% 1874
2025
Q1 		$511K Buy
158,288
+105,544
+200% +$497K ﹤0.01% 2070
2024
Q4 		$294K Sell
52,744
-112,449
-68% -$882K ﹤0.01% 2240
2024
Q3 		$1.79M Sell
165,193
-20,673
-11% -$343K ﹤0.01% 1412
2024
Q2 		$3.9M Sell
185,866
-71,880
-28% -$1.8M 0.01% 1110
2024
Q1 		$8.21M Buy
+257,746
New +$6.58M 0.01% 811
2023
Q2 		– Sell
-33,954
Closed -$584K – 2611
2023
Q1 		$584K Sell
33,954
-35,793
-51% -$696K ﹤0.01% 2036
2022
Q4 		$1.55M Buy
+69,747
New +$1.08M ﹤0.01% 1865
2022
Q1 		– Sell
-3,317
Closed -$73K – 3540
2021
Q4 		$73K Buy
+3,317
New +$81.3K ﹤0.01% 3466
2021
Q2 		– Sell
-18,760
Closed -$814K – 2775
2021
Q1 		$814K Buy
18,760
+11,324
+152% +$502K ﹤0.01% 1759
2020
Q4 		$308K Buy
+7,436
New +$307K ﹤0.01% 1644

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Marshall Wace's FDMT Position: Q2 2026 in Review

Marshall Wace increased its 4D Molecular Therapeutics (FDMT) stake by 28% in Q2 2026, buying an estimated $45K and bringing the position to 21,342 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Marshall Wace first reported a position in FDMT in Q4 2020 and has held it in 15 quarters since. The position peaked at $8.21M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Marshall Wace held 21,342 shares of 4D Molecular Therapeutics worth $284K as of Q2 2026.
  • Marshall Wace bought 4,614 4D Molecular Therapeutics shares in Q2 2026, an estimated $45K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2744 holding.
  • Marshall Wace first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 15 quarters since.
  • Marshall Wace's 4D Molecular Therapeutics position peaked at $8.21M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.